J&J single-dose vaccine 72% effective in preventing Covid-19
In a sub-study of 6,000 volunteers in SA, the vaccine was 89% effective, with 95% of cases in the SA trial infected with the SA variant
29 January 2021 - 15:48
Johnson & Johnson said on Friday that its single-dose vaccine was 72% effective in preventing Covid-19 in the US but a lower rate of 66% was observed globally in the large trial conducted across three continents and against multiple variants.
In the trial of nearly 44,000 volunteers, the level of protection against moderate and severe Covid-19 was 66% in Latin America and just 57% in SA, where a particularly worrying variant of the coronavirus is circulating...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.